Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
CRISPR: First Cut Has Deepest Value - Buy And Hold
01:33pm, Monday, 31'st May 2021
CRISPR is a pioneer in the gene editing space, licensing Nobel Prize winning technology to try to treat inherited diseases, cancers, and hematological conditions. The company's lead candidate is CTX00
4 Unstoppable Healthcare Stocks to Buy on the Dip
06:05am, Wednesday, 26'th May 2021
They're well below peak levels set earlier this year. But they could be huge winners over the long run.
Crispr Therapeutics: Pullback Has Created Opportunity
01:12am, Tuesday, 25'th May 2021
Crispr Therapeutics: Pullback Has Created Opportunity
CAMBRIDGE, Mass. and ZUG, Switzerland and BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two abstrac
With 1 Cure Behind It, This Breakthrough Biotech Takes Aim at a Bigger Market
06:40am, Friday, 07'th May 2021
One company is setting itself apart in a crowded field.
Best Biotech Stocks & ETFs for mRNA, Gene Editing
05:17pm, Thursday, 29'th Apr 2021
Here is what you should know about investing in these life changing technologies.
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
08:30am, Thursday, 29'th Apr 2021
ZUG, Switzerland and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for se
CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
04:01pm, Wednesday, 28'th Apr 2021
ZUG, Switzerland and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for se
CRISPR Therapeutics (CRSP) Q1 Earnings Miss, Revenues Rise Y/Y
10:47am, Wednesday, 28'th Apr 2021
CRISPR Therapeutics' (CRSP) earnings and revenues miss estimates in the first quarter of 2021. Focus on pipeline development.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
06:02pm, Tuesday, 27'th Apr 2021
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -4.14% and -89.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock
Skyworks Lifts Nasdaq Ahead of Earnings; CRISPR Keeps Moving Forward
02:47pm, Monday, 26'th Apr 2021
The Nasdaq gained ground to start the week.
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today
02:18pm, Monday, 26'th Apr 2021
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQ
Crispr Therapeutics: Strong Partnership And Data Development
08:48am, Monday, 26'th Apr 2021
In recent years, gene therapy and gene editing are growing in prominence. Leading the gene-editing innovation, CRISPR Therapeutics is poised to make history in this space. The latest data for the sick
BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the Eur
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
06:47pm, Friday, 23'rd Apr 2021
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $126.55, marking a +0.52% move from the previous day.
